ACD/Labs launches ACD/Spectrus Platform in PITTCON 2014 ACD/Labs.

The Spectrus advancements will impact groupings that function in areas such as preformulation, extractables and leachables, DMPK , organic synthesis, and labs focused on impurity control, identification, and characterization.. ACD/Labs launches ACD/Spectrus Platform in PITTCON 2014 ACD/Labs, a respected cheminformatics business, announced today to PITTCON 2014 the brand new launch of their ACD/Spectrus System that enables organizations to use chemical context to their spectroscopy, spectrometry, and chromatography content. The ACD/Spectrus Platform makes it easier than ever for organizations to manage unified analytical data from multiple methods and instruments, and combine it with chemical and structural details, in a vendor-agnostic homogeneous environment.We have become excited by these brand-new data with ALN-AT3 which demonstrate normalization of thrombin generation and improvement of hemostasis in hemophilia versions. Most importantly, we’ve demonstrated that ALN-AT3 can completely correct thrombin generation in a nonhuman primate hemophilia 'inhibitor' model, providing key proof of concept for our program. Finally, by administering exaggerated doses of ALN-AT3 to crazy type and hemophilia pets extremely, we've demonstrated our RNAi therapeutic has a very wide therapeutic index in the hemophilia setting.